Company prepares to launch Moxatag(TM), the first and only FDA-approved
once-daily amoxicillin, in the first quarter of 2009
GERMANTOWN, Md., Nov. 13 /PRNewswire-FirstCall/ --
-- MiddleBrook Pharmaceuticals received stockholder approval for and
closed a $100 million financing transaction with Equity Group
Investments, L.L.C. (EGI). (Sept.)
-- MiddleBrook repurchased the Keflex(R) assets for approximately $11.0
million from Deerfield Management and redeemed the Deerfield warrant
for $8.8 million in conjunction with the EGI transaction. (Sept.)
-- John Thievon became president & CEO, and David Becker became executive
vice president & CFO effective upon the close of the EGI transaction.
-- The MiddleBrook team was expanded to include additional senior leaders
with proven track records in commercial operations. (Sept. - Nov.)
-- MiddleBrook engaged TalenTactics(TM) to lead its national sales force
hiring efforts and teamed with VCG & Associates to obtain managed-care
coverage for Moxatag (extended-release amoxicillin) Tablets, 775mg.
-- The Company's Moxatag patents were listed in FDA's Orange Book. (Oct.)
-- MiddleBrook President & CEO John Thievon presented at the 10th Annual
Rodman & Renshaw Healthcare Conference. (Nov.)
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) today announced financial and operational results for the quarter ended Sept. 30, 2008.
MiddleBrook President & CEO John Thievon said, "We have made
significant progress since September. We have expanded the MiddleBrook
senior leadership team, and our accomplished sc
|SOURCE MiddleBrook Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved